Skip to main content

Web Exclusives

FDA Approvals, In the News
Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation
Read More
FDA Approvals
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Read More
FDA Approvals
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Read More
FDA Approvals, In the News
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Read More
FDA Approvals
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Read More
FDA Approvals, In the News
April 16, 2019 – FDA Approvals, News & Updates
Read More
FDA Approvals
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Read More
FDA Approvals
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
Read More
FDA Approvals
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Read More
FDA Approvals
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
Read More
Page 19 of 37
Results 181 - 190 of 362